Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27897843 | 0.88 | KMT2A (0.59) | HSD17B10KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL4232672 | 0.84 | ITGA4 (0.49) | KMT2AALDH1A1MEN1TDP1SMN1; SMN2 | |
| SCHEMBL11068744 | 0.84 | ALDH1A1 (0.50) | KMT2ALMNAALDH1A1MEN1TDP1 | |
| SCHEMBL9767892 | 0.82 | KMT2A (0.46) | HSD17B10FFAR4KMT2APOLBLMNA | |
| SCHEMBL14930290 | 0.82 | KMT2A (0.46) | KMT2AALDH1A1MEN1TDP1SMN1; SMN2 | |
| SCHEMBL10034915 | 0.82 | KMT2A (0.46) | KMT2AALDH1A1MEN1TDP1SMN1; SMN2 | |
| SCHEMBL4645930 | 0.82 | MEN1 (0.48) | KMT2APOLBLMNAALDH1A1MEN1 | |
| SCHEMBL9767984 | 0.82 | FFAR4 (0.50) | HSD17B10FFAR4KMT2APOLBLMNA | |
| SCHEMBL863170 | 0.81 | HSD17B10 (0.55) | HSD17B10FFAR4KMT2ALMNAKDM4E | |
| SCHEMBL28695929 | 0.81 | HSD17B10 (0.58) | HSD17B10FFAR4KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | AVPR2, AVPR1A, AVPR1B | HSD17B10 1915/4885FFAR4 621/4885KMT2A 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.